COLLEGE NEWS

New epidermolysis bullosa trial

A new clinical trial, the DELIVERS study, is now recruiting. The trial aims to evaluate the safety and efficacy of diacerein 1% ointment (CCP‐020) for the treatment of epidermolysis bullosa simplex (EBS).

The trial is sponsored by Castle Creek Pharmaceuticals and is being conducted in the United State of America, Europe, Israel and Australia. Please note that participation in any trial is an individual decision and entirely voluntary.

Visit the Clinical Trials or Delivers websites for further information.

Enquiries can be directed to Helen Dickenson-Panas at Premier Specialists on 02 9598 5800 or by email.